PR Newswire Clinical TrialsOriginal article
First Patient Dosed in Phase III Perioperative Study of Cadonilimab (PD-1/CTLA-4) in Colon Cancer
Phase 3cadonilimabPositive
AI Analysis
Summary
Akeso announced first patient dosing in Phase III COMPASSION-40 study evaluating cadonilimab, a PD-1/CTLA-4 bispecific antibody, as monotherapy in perioperative colon cancer treatment.
Clinical Trial Data
Phase
Phase III
NCT ID
Outcome Details
First patient dosed in Phase III perioperative study
Importance:5/10
Sentiment:
0.50
Phase_3oncologyimmunotherapybispecific_antibodyPD-1CTLA-4trial_initiation
Related Companies
Read the original article
Published by PR Newswire Clinical Trials on October 10, 2026 4:41 AM